Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04340024

Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients

Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Nasopharyngeal Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Head and Neck Neoplasms Male Urogenital Diseases Nasopharyngeal Diseases Nasopharyngeal Neoplasms Neoplasms Neoplasms by Site Other Cancer Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Pharyngeal Diseases Pharyngeal Neoplasms Prostate Cancer Prostatic Diseases Prostatic Neoplasms Stomatognathic Diseases Urogenital Diseases Urogenital Neoplasms

Age range

21 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

National Cancer Center Singapore

Singapore, 169690

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with severe side effects from radiotherapy
  • Patients with a type of cancer that is associated with sensitivity to radiotherapy

Exclusion criteria

  • Age of patient must be between 21 (inclusive) and 99 (exclusive)

Treatment and study plan

Primary outcomes

  1. To identify genes or molecular pathways that are associated with radiation sensitivity in blood and tissue samples

    Time frame: Blood is taken at informed consent; tissue is from archived sample

    Whole exome sequencing, single nucleotide polymorphism (SNP) assays

  2. Change in immune profile of blood and tissue after radiation

    Time frame: Blood is taken at informed consent; tissue is from archived sample

    Mass cytometry using CyTOF technology will be used to detect the immune cell population

  3. To identify proteins that are associated with radiation sensitivity in tissue samples

    Time frame: Tissue is from archived sample

    Immunohistochemistry will be used to detect protein expression

  4. To identify RNA expression pathways that are associated with radiation sensitivity in blood and tissue samples

    Time frame: Blood is taken at informed consent; tissue is from archived sample

    RNA sequencing

Study contacts

Contact information is provided by the study sponsor or research team.

Enya Ong

CONTACT

[email protected]

+65 6436 8000

Melvin Chua, MD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

National Cancer Centre, Singapore

Other

Collaborators

  • Decipher Biosciences
  • Duke-NUS Graduate Medical School
  • Ferring Pharmaceuticals
  • ImmunoSCAPE
  • National Medical Research Council (NMRC), Singapore

Registry information

Important dates

Study start
2015
Primary completion
2026
Study completion
2026
First posted
Apr 9, 2020
Registry last updated
Jun 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.